Micafungin: A new echinocandin

Clinical Infectious Diseases

Volumn 42, Issue 8, 2006, Pages 1171-1178

  Chandrasekar, P H ^a   Sobel, J D ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; 1,3 BETA GLUCAN SYNTHASE INHIBITOR; CASPOFUNGIN; CYCLOSPORIN; CYTOCHROME P450; DIAZEPAM; ECHINOCANDIN; ENZYME ACTIVATOR; ENZYME INHIBITOR; FLUCONAZOLE; METHOTREXATE; MICAFUNGIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEW DRUG; NIFEDIPINE; RAPAMYCIN; RAVUCONAZOLE; RIFAMPICIN; RITONAVIR; TSUKUBAENOLIDE; UNCLASSIFIED DRUG; VORICONAZOLE; WARFARIN;

ANAPHYLAXIS; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDA ALBICANS; CLINICAL TRIAL; DIARRHEA; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; EOSINOPHILIA; ESOPHAGUS CANDIDIASIS; FEVER; HEMOLYSIS; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; LIVER DYSFUNCTION; MAXIMUM PLASMA CONCENTRATION; MOULD; MYCOSIS; NAUSEA; NEUTROPENIA; NONHUMAN; PHLEBITIS; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; TREATMENT INDICATION;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, FUNGAL; ENZYME INHIBITORS; GLUCOSYLTRANSFERASES; HUMANS; LIPOPROTEINS; MICE; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC;

EID: 33645781302     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/501020     Document Type: Review

References (64)

1. Barrett D. From natural products to clinically useful antifungals. Biochim Biophys Acta 2002; 1587:224-33.
2. Mikamo H, Sato Y, Tamaya T. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J Antimicrob Chemother 2000; 46:485-7.
3. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-51.
4. Kurtz MB, Douglas CM. Lipopeptide inhibitors of fungal glucan synthase. J Med Vet Mycol 1997; 35:79-86.
5. Hatano K, Morishita Y, Nakai T, Ikeda F. Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus. J Antibiot (Tokyo) 2002; 55:219-22.
6. Nishiyama Y, Uchida K, Yamaguchi H. Morphological changes of Candida albicans induced by micafungin (FK463), a water-soluble echinocandin-like lipopeptide. J Electron Microsc (Tokyo) 2002; 51:247-55.
7. Nakai T, Watabe E, Otomo K, Hatano K, Ikeda F. In vitro pharmacodynamic characterization of micafungin against 5 different Candida species [abstract A-494]. In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002:3.
8. Nakai T, Uno J, Otomo K, et al. In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds. Chemotherapy 2002; 48:78-81.
9. Chiou CC, Mavrogiorgos N, Tillem E, Hector R, Walsh TJ. Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob Agents Chemother 2001; 45:3310-21.
10. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002; 46:1773-80.
11. Borg-von Zepelin M, Zaschke K, Gross U, Monod M, Muller FM. Effect of micafungin (FK463) on Candida albicans adherence to epithelial cells. Chemotherapy 2002; 48:148-53.
12. Gil-Lamaignere C, Salvenmoser S, Hess R, Muller FM. Micafungin enhances neutrophil fungicidal functions against Candida pseudohyphae. Antimicrob Agents Chemother 2004; 48:2730-2.
13. Laverdiere M, Hoban D, Restieri C, Habel F. In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antimicrob Chemother 2002; 50:119-23.
14. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003; 47:3149-54.
15. Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000; 44:57-62.
16. Uchida K, Nishiyama Y, Yokota N, Yamaguchi H. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. J Antibiot (Tokyo) 2000; 53:1175-81.
17. Tomishima M, Ohki H, Yamada A, et al. FK463, a novel water-soluble echinocandin lipopeptide: synthesis and antifungal activity. J Antibiot (Tokyo) 1999; 52:674-6.
18. Ito M, Nozu R, Kuramochi T, et al. Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice. Antimicrob Agents Chemother 2000; 44:2259-62.
19. Groll AH, Stergiopoulou T, Roilides E, Walsh TJ. Micafungin: pharmacology, experimental therapeutics and clinical applications. Expert Opin Investig Drugs 2005; 14:489-509.
20. Moudgal V, Little T, Boikov D, Vazquez JA. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005; 49:767-9.
21. Stone JA, Holland SD, Wickersham PJ, et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002; 46:739-45.
22. Fromtling RA. Micafungin sodium (FK-463). Drugs Today (Barc) 2002; 38:245-57.
23. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005;49:3317-24.
24. Carver PL. Micafungin. Ann Pharmacother 2004; 38:1707-21.
25. Ninomiya M, Mikamo H, Tanaka K, Watanabe K, Tamaya T. Efficacy of micafungin against deep-seated candidiasis in cyclophosphamide-induced immunosuppressed mice. J Antimicrob Chemother 2005; 55: 587-90.
26. Maesaki S, Hossain MA, Miyazaki Y, Tomono K, Tashiro T, Kohno S. Efficacy of FK463, a (1,3)-β-D-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice. Antimicrob Agents Chemother 2000; 44:1728-30.
27. Warn PA, Sharp A, Morrissey G, Denning DW. In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis. J Antimicrob Chemother 2002; 50:1071-4.
28. Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003; 187:1834-43.
29. Matsumoto S, Wakai Y, Nakai T, et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob Agents Chemother 2000; 44:619-21.
30. Luque JC, Clemons KV, Stevens DA. Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother 2003; 47:1452-5.
31. Graybill JR, Bocanegra R, Gonzalez GM, Najvar LK. Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin. J Antimicrob Chemother 2003; 52:656-62.
32. Warn PA, Morrissey G, Morrissey J, Denning DW. Activity of mica-fungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. J Antimicrob Chemother 2003; 51:913-9.
33. Ikeda F, Wakai Y, Matsumoto S, et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother 2000; 44:614-8.
34. Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002; 46: 1857-69.
35. Chandrasekar PH, Cutright JL, Manavathu EK. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis. Clin Microbiol Infect 2004; 10:925-8.
36. Kohno S, Maesaki S, Iwakawa J, et al. Synergistic effects of combination of FK-463 with amphotericin B: enhanced efficacy in murine model of invasive pulmonary aspergillosis [abstract 1686]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto, Canada). Washington, DC: American Society for Microbiology, 2000:388.
37. Nakajimi M, Tamada S, Yoshida K, et al. Pathological findings in a murine pulmonary aspergillosis model: treatment with FK463, amphotericin B and a combination of FK463 and amphotericin B [abstract 1685]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto, Canada). Washington, DC: American Society for Microbiology, 2000:387.
38. Pettengell K, Mynhardt J, Kluyts T, Lau W, Facklam D, Buell D. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther 2004; 20:475-81.
39. de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004; 39:842-9.
40. de Wet NT, Bester AJ, Viljoen JJ, et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 2005; 21: 899-907.
41. Krause DS, Simjee AE, van Rensburg C, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004; 39:770-5.
42. Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113:294-9.
43. Anaissie E, Ostrosky-Zeichner L, Kontoyiannis D, et al. Micafungin, an echinocandin antifungal agent for the treatment of new and refractory candidemia [abstract 35]. In: Program and abstracts of the 13th Focus on Fungal Infections Meeting (Maui, Hawaii). 2003.
44. Kontoyiannis D, Buell D, Frisbee-Hume S, Reddy B, Rolston K. Initial experience with FK463 for the treatment of candidemia in cancer patients [abstract J1629]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001:399.
45. Kohno S, Masaoka T, Yamaguchi H, et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004; 36:372-79.
46. Matsumoto Y, Dogru M, Goto E, Fujishima H, Tsubota K. Successful topical application of a new antifungal agent, micafungin, in the treatment of refractory fungal corneal ulcers: report of three cases and literature review. Cornea 2005; 24:748-53.
47. Ullmann AJ, van Burik A, McSweeney P, et al. An open phase II study of the efficacy of micafungin (FK463) alone and in combination for the treatment of invasive aspergillosis (IA) in adults and children [abstract 0400]. In: Program and abstracts of the 13th European Congress of Clinical Microbiology and Infectious diseases (Glasgow, UK). Clin Microbiol Infect 2003;9(Suppl 1):72.
48. Ratanatharathorn V, Flynn P, van Burik J, McSweeney P, Niederwieser D, Kontoyiannis D. Micafungin in combination with systemic anti-fungal agents in the treatment of refractory aspergillosis (RA) in bone marrow transplant (BMT) patients [abstract 2472]. In: Program and abstracts of the 44th Annual American Society of Hematology Meeting. Blood 2002 100:67a.
49. Ota S, Tanaka J, Kahata K, et al. Successful micafungin (FK463) treatment of invasive pulmonary aspergillosis in a patient with acute lymphoblastic leukemia in a phase II study Int J Hematol 2004; 79:390-3.
50. Yokote T, Akioka T, Oka S, et al. Successful treatment with micafungin of invasive pulmonary aspergillosis in acute myeloid leukemia, with renal failure due to amphotericin B therapy. Ann Hematol 2004; 83: 64-6.
51. Singer MS, Seibel NL, Vezina G, Choi SS, Dinndorf PA. Successful treatment of invasive aspergillosis in two patients with acute myelogenous leukemia. J Pediatr Hematol Oncol 2003; 25:252-6.
52. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39:1407-16.
53. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96:2055-61.
54. Shimoeda S, Ohta S, Kobayashi H, et al. Analysis of the blood level of micafungin involving patients with hematological diseases: new findings regarding combination therapy with tacrolimus. Biol Pharm Bull 2005; 28:477-80.
55. Hebert MF, Blough DK, Townsend RW, et al. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005; 45:1018-24.
56. Hebert MF, Townsend RW, Austin S, et al. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005; 45:954-60.
57. Micafungin (mycamine) for fungal infections. Deerfield, IL: Astellas, 2005.
58. Caspofungin (Cancidas) for aspergillosis. Med Lett Drugs 2001; 43:58.
59. Marr KA, Hachem R, Papanicolaou G, et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl Infect Dis 2004; 6:110-6.
60. Sanz-Rodriguez C, Lopez-Duarte M, Jurado M, et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant 2004; 34:13-20.
61. Mora-Duarte, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9.
62. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351:1391-402.
63. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-71.
64. Odio CM, Araya R, Pinto LE, et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004; 23:1093-7.